Recent federal budget decisions signal renewed national momentum for cancer research—including meaningful progress for pancreatic cancer. In March 2026, Congress approved appropriations that increase funding for both the National Institutes of Health (NIH) and the National Cancer Institute (NCI), reversing previously proposed cuts and reaffirming bipartisan support for lifesaving science.
The NIH will receive approximately $48.7 billion, with the NCI allocated $7.4 billion, sustaining vital biomedical research across the country. Notably, the Defense Appropriations Bill also includes $20 million specifically dedicated to pancreatic cancer research—a historic investment that will help accelerate new breakthroughs in early detection, treatment, and survival outcomes.
While not all of this funding is earmarked directly for pancreatic cancer, these increases strengthen the research ecosystem that drives innovation forward—including the types of high-risk, high-reward projects Sky Foundation helps seed at institutions across the U.S.
Sky Foundation applauds this renewed commitment to scientific discovery and will continue advocating for increased awareness, funding, and equity in the fight against pancreatic cancer.